Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents. [electronic resource]
Producer: 20100309Description: 36-42 p. digitalISSN:- 1537-453X
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- adverse effects
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Colorectal Neoplasms -- drug therapy
- Drug Therapy, Combination
- Erythropoietin -- adverse effects
- Female
- Hemoglobins -- metabolism
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Pilot Projects
- Prognosis
- Recombinant Proteins
- Retrospective Studies
- Survival Rate
- Thromboembolism -- chemically induced
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.